Goldman Myla Lai

Goldman Myla Lai is a declared insider at 5 companies (senior executive); the most frequent names are Labcorp Holdings Inc., West Pharmaceutical Services Inc and Sequenom Inc. Over a trading history stretching from 5 January 2006 to 8 July 2026, the count stands at 347 filings.

On the open market, the record shows 4 purchases worth €107k and 284 sales worth €13.5M. Taken together, the sales exceed the purchases by €13.4M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 37 share grants and 19 option exercises.

A typical purchase (the median) is worth €6,922.

On 9 July 2026 came the latest disclosure, an option exercise in Quanterix Corp. The most recent open-market purchase was published on 12 June 2023, 1,246 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.